Technology area: Biotechnology & Pharmaceuticals
2 pending office actions • 2 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready • 1 patents granted in the last 365 days
Skintech Life Science Limited currently has 1 pending office action in the Biotechnology & Pharmaceuticals technology area. This single matter is assigned to a distinct examiner and is located within 1 distinct art unit. Soroush, Layla is the busiest examiner for the portfolio, currently overseeing the 1 pending office action. This indicates a singular and focused point of contact for the company's current prosecution effort.
For a company with this specific workload, the examiner's preferences and the art unit's historical trends will be the primary factors in determining the immediate outcome. Practitioners should focus on establishing a clear line of communication with Soroush, Layla, as this individual holds the entirety of the company's current pending workload. Because the prosecution is limited to a single art unit, the company can tailor its strategy to the specific examination standards of that unit. This focused approach may allow for more efficient resolution of the pending office action compared to portfolios spread across multiple units. The concentrated nature of this portfolio in the Biotechnology & Pharmaceuticals sector requires a highly targeted prosecution strategy.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 2 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| SOROUSH, LAYLA | 1 | 40.4% | +43.6% |
| CHONG, YONG SOO | 1 | 43.8% | +41.7% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18935357 | TOPICAL DIM COMPOSITIONS AND USES THEREOF | SOROUSH, LAYLA | — |
| 18794896 | SUBLINGUAL OR BUCCAL ADMINISTRATION OF DIM FOR TREATMENT OF SKIN DISEASES | CHONG, YONG SOO | — |
| Art Unit | Apps |
|---|---|
| 1622 | 1 |
| 1623 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18935357 | TOPICAL DIM COMPOSITIONS AND USES THEREOF | SOROUSH, LAYLA | 1622 | §103 | Non-Final OA | — | Pending | Nov 01, 2024 |
| 18794896 | SUBLINGUAL OR BUCCAL ADMINISTRATION OF DIM FOR TREATMENT OF SKIN DISEASES | CHONG, YONG SOO | 1623 | §103 | Non-Final OA | — | Pending | Aug 05, 2024 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialSkintech Life Science Limited has 2 pending office actions as of November 2026, spread across 2 art units and 2 examiners.
Layla Soroush has the most, with 1 of Skintech Life Science Limited's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.